In the original article, there were some errors. “Comorbidities” was misspelled. All instances of the incorrect spelling should be corrected to read “comorbidities”.
The acronym for chronic obstructive pulmonary disease was incorrectly spelled. This should be COPD.
In the original articles, there were some mistakes in Table 2.
The section “Taquism” should be named “Smoking”. The row “Taquism” in the “Outcomes” section was deleted. “Immunossupression” should read “Immunocompression”.
The corrected table appears below.
Table 2
| Variables | Survival | No survival | p-value | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Sex | |||||
| Male | 340,076 | 50.40% | 50,340 | 64.10% | <0.0001 |
| Female | 334,244 | 49.60% | 28,152 | 35.90% | |
| Group Age | |||||
| <2 years | 2,383 | 0.40% | 121 | 0.20% | <0.0001 |
| 2.1–5.9 | 2,557 | 0.40% | 33 | 0.00% | |
| 6–9.9 | 4,255 | 0.60% | 39 | 0.00% | |
| 10–18.9 | 15,628 | 2.30% | 102 | 0.10% | |
| 19– <40 | 284,456 | 42.20% | 4,337 | 5.50% | |
| 40– <50 | 151,988 | 22.50% | 9,252 | 11.80% | |
| 50– <60 | 114,663 | 17.00% | 17,446 | 22.20% | |
| 60– <70 | 60,976 | 9.00% | 21,766 | 27.70% | |
| 70–79.9 | 26,723 | 4.00% | 16,741 | 21.30% | |
| 80+ | 10,691 | 1.60% | 8,655 | 11.00% | |
| Type | |||||
| Ambulatory | 564,547 | 83.70% | 8,977 | 11.40% | <0.0001 |
| Hospitalization | 109,773 | 16.30% | 69,515 | 88.60% | |
| Comorbidities | |||||
| Diabetes | 85,614 | 12.70% | 30,096 | 38.30% | <0.0001 |
| COPD | 7,085 | 1.10% | 3,813 | 4.90% | <0.0001 |
| Asthma | 17,889 | 2.70% | 1,578 | 2.00% | <0.0001 |
| Immunocompression | 6,159 | 0.90% | 1,935 | 2.50% | <0.0001 |
| Hypertension | 109,956 | 16.30% | 35,221 | 44.90% | <0.0001 |
| Cardiovascular disease | 10,572 | 1.60% | 4,175 | 5.30% | <0.0001 |
| Obesity | 116,071 | 17.20% | 19,182 | 24.40% | <0.0001 |
| Renal chronic disease | 8,635 | 1.30% | 5,529 | 7.00% | <0.0001 |
| Smoking | 48,622 | 7.20% | 6,264 | 8.00% | <0.0001 |
| Outcomes | |||||
| Pneumonia | 79,584 | 11.80% | 58,078 | 74.00% | <0.0001 |
| Invasive mechanical ventilation | 5,898 | 0.90% | 25,539 | 32.50% | <0.0001 |
| Intensive care unit | 7,514 | 1.10% | 7,890 | 10.10% | <0.0001 |
Differences between survivors and non-survivors with SARS CoV-2.
The value of p was calculated by X2 test.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
Mexico, SARS-CoV-2, survival analysis, cohort study, comorbidity, COVID-19 outbreak
Citation
Márquez-González H, Méndez-Galván JF, Reyes-López A, Klünder-Klünder M, Jiménez-Juárez R, Garduño-Espinosa J and Solórzano-Santos F (2021) Corrigendum: Coronavirus Disease-2019 Survival in Mexico: A Cohort Study on the Interaction of the Associated Factors. Front. Public Health 9:754703. doi: 10.3389/fpubh.2021.754703
Received
06 August 2021
Accepted
12 August 2021
Published
29 September 2021
Volume
9 - 2021
Edited and reviewed by
Burc Barin, Emmes Corporation, United States
Updates
Copyright
© 2021 Márquez-González, Méndez-Galván, Reyes-López, Klünder-Klünder, Jiménez-Juárez, Garduño-Espinosa and Solórzano-Santos.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fortino Solórzano-Santos solorzanof056@gmail.com
This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.